Related Experiment Video
Updated: Apr 21, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Comparing comparators: a look at control arms in kidney cancer studies over the years
S Bracarda1, C Porta2, M Sisani1
1Department of Medical Oncology, Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy.
Abstract:
In the past decade, an increasing number of frequently positive randomised clinical trials have been completed, allowing new consideration of the present therapeutic armamentarium for advanced renal cell carcinoma. These studies were predominantly designed to compare the experimental drugs with 1 of 2 active control arms: interferon alpha-2a or sorafenib. Different from expectations, the final results of some of these studies were not in line with the predictions, and the reasons have not been fully investigated. Consequently, there is a great need for careful analysis of the studies carried out so far, chiefly the role and validity of the control arms. In this regard, the examination of patient baseline characteristics and other factors of potential interest seems fundamental for a correct analysis of the results of these trials and consequent optimal use of the available targeted agents.
Insights
Recent clinical trials for advanced renal cell carcinoma yielded unexpected results. A thorough analysis of control arms and patient characteristics is crucial for understanding targeted therapy effectiveness.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) treatment has seen numerous positive randomized clinical trials in the last decade.
- These trials primarily compared new drugs against interferon alpha-2a or sorafenib as active controls.
- Some trial outcomes deviated from predictions, necessitating further investigation into underlying reasons.
Purpose of the Study:
- To critically analyze completed randomized clinical trials for advanced RCC.
- To evaluate the role and validity of interferon alpha-2a and sorafenib as control arms in these trials.
- To identify factors influencing trial results for optimal use of targeted agents.
Main Methods:
- Review of recently completed randomized clinical trials in advanced RCC.
- Analysis of study designs comparing experimental drugs against specific active control arms (interferon alpha-2a, sorafenib).
- Examination of patient baseline characteristics and other relevant factors within trial data.
Main Results:
- Some trials did not produce expected results, indicating a need for deeper analysis.
- The effectiveness of control arms in reflecting true treatment efficacy requires scrutiny.
- Variations in patient populations and other factors may impact observed outcomes.
Conclusions:
- A comprehensive review of advanced RCC trials is essential.
- The validity and selection of control arms significantly influence study interpretation.
- Understanding patient characteristics is key to optimizing the use of targeted therapies in advanced RCC.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Kidney Transplant II: Surgical Procedure
Blood and Nerve Supply to the Kidney
Bloody Supply to the Kidneys:
The kidneys receive their blood supply from the renal arteries, which branch off from the abdominal aorta—the main artery supplying the abdomen and lower body. The renal arteries enter the kidneys at the hilum, a notch on the medial side of...
Kidney Transplant I: Introduction
Chronic Kidney Disease III: Interprofessional Care